These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 19283255)

  • 1. Quadrivalent HPV vaccination reactions--more hype than harm.
    Douglas RJ
    Aust Fam Physician; 2009 Mar; 38(3):139-42. PubMed ID: 19283255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance.
    Gold MS; McIntyre P
    Sex Health; 2010 Sep; 7(3):320-4. PubMed ID: 20719221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HPV vaccination - a paradigm shift in public health.
    May J
    Aust Fam Physician; 2007 Mar; 36(3):106-11. PubMed ID: 17339969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine.
    Block SL; Brown DR; Chatterjee A; Gold MA; Sings HL; Meibohm A; Dana A; Haupt RM; Barr E; Tamms GM; Zhou H; Reisinger KS
    Pediatr Infect Dis J; 2010 Feb; 29(2):95-101. PubMed ID: 19952863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics.
    Pomfret TC; Gagnon JM; Gilchrist AT
    J Clin Pharm Ther; 2011 Feb; 36(1):1-9. PubMed ID: 21198715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prophylactic role for the human papillomavirus quadrivalent vaccine in males.
    Yancey AM; Pitlick JM; Forinash AB
    Ann Pharmacother; 2010; 44(7-8):1314-8. PubMed ID: 20501891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CNS demyelination and quadrivalent HPV vaccination.
    Sutton I; Lahoria R; Tan I; Clouston P; Barnett M
    Mult Scler; 2009 Jan; 15(1):116-9. PubMed ID: 18805844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US.
    Dunne EF; Datta SD; E Markowitz L
    Cancer; 2008 Nov; 113(10 Suppl):2995-3003. PubMed ID: 18980283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human papillomavirus and the HPV vaccine: are the benefits worth the risks?
    Knudtson M; Tiso S; Phillips S
    Nurs Clin North Am; 2009 Sep; 44(3):293-9. PubMed ID: 19683091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New quadrivalent HPV vaccine developments.
    Tovar JM; Bazaldua OV
    Postgrad Med; 2008 Nov; 120(4):14-6. PubMed ID: 19020361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing human papillomavirus vaccine efficacy and safety.
    Hendrix SL
    J Am Osteopath Assoc; 2008 Apr; 108(4 Suppl 2):S8-S12. PubMed ID: 18463363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine.
    Giuliano AR; Lazcano-Ponce E; Villa L; Nolan T; Marchant C; Radley D; Golm G; McCarroll K; Yu J; Esser MT; Vuocolo SC; Barr E
    J Infect Dis; 2007 Oct; 196(8):1153-62. PubMed ID: 17955433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Considerations for human papillomavirus (HPV) vaccination of mid-adult women in the United States.
    Grant LA; Dunne EF; Chesson H; Markowitz LE
    Vaccine; 2011 Mar; 29(13):2365-70. PubMed ID: 21277406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects.
    Grimaldi-Bensouda L; Guillemot D; Godeau B; Bénichou J; Lebrun-Frenay C; Papeix C; Labauge P; Berquin P; Penfornis A; Benhamou PY; Nicolino M; Simon A; Viallard JF; Costedoat-Chalumeau N; Courcoux MF; Pondarré C; Hilliquin P; Chatelus E; Foltz V; Guillaume S; Rossignol M; Abenhaim L;
    J Intern Med; 2014 Apr; 275(4):398-408. PubMed ID: 24206418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of effects on fertility and developmental toxicity of a quadrivalent HPV vaccine in Sprague-Dawley rats.
    Wise LD; Wolf JJ; Kaplanski CV; Pauley CJ; Ledwith BJ
    Birth Defects Res B Dev Reprod Toxicol; 2008 Dec; 83(6):561-72. PubMed ID: 19025783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HPV vaccination catch up program - utilisation by young Australian women.
    Weisberg E; Bateson D; McCaffery K; Skinner SR
    Aust Fam Physician; 2009; 38(1-2):72-6. PubMed ID: 19283241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HPV vaccine: immersed in controversy.
    Ohri LK
    Ann Pharmacother; 2007 Nov; 41(11):1899-902. PubMed ID: 17848419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health.
    Harper DM
    Public Health Genomics; 2009; 12(5-6):319-30. PubMed ID: 19684444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008.
    Koulova A; Tsui J; Irwin K; Van Damme P; Biellik R; Aguado MT
    Vaccine; 2008 Dec; 26(51):6529-41. PubMed ID: 18805453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quadrivalent Human Papillomavirus recombinant vaccine associated lipoatrophy.
    Ojaimi S; Buttery JP; Korman TM
    Vaccine; 2009 Aug; 27(36):4876-8. PubMed ID: 19555713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.